Study S002766

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of DR10624 in Subjects With Severe Hypertriglyceridemia Receiving Stable Lipid-Modifying Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07693777
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 480
Start: 2026-08-17
Primary completion: 2029-02-14
Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
Conditions: Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia
Interventions: BIOLOGICAL:DR10624 Injection; OTHER:Matching Placebo for DR10624
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change from baseline in central laboratory-measured fasting serum triglyceride at Week 26 [Baseline to Week 26 of double-blind treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.